Income Statement
ASPIRE BIOPHARMA HOLDINGS, INC.
ASBP
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
0.01 | 0.00 | - | - |
|
Gross Profit
|
0.00 | - | - | - |
|
Operating Expenses
|
19.35 | 3.09 | 1.34 | 0.98 |
|
Research & Development
|
0.92 | 0.14 | - | - |
|
Selling, General & Administrative
|
17.64 | 3.09 | 1.34 | 0.98 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-19.35 | -3.09 | -1.34 | -0.98 |
|
Non-Operating Income
|
-5.13 | -0.10 | 5.80 | 4.32 |
|
Interest Income
|
- | 0.55 | 5.81 | 4.32 |
|
Interest Expense
|
- | 0.89 | 0.01 | - |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
-24.48 | -1.31 | - | - |
|
Income Tax Expense
|
0.00 | 0.00 | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-24.48 | 1.31 | 4.46 | 3.34 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-19.35 | -3.09 | -1.34 | -0.98 |
|
Earnings Per Share (Basic)
|
- | 0.00 | 0.23 | 0.11 |
|
Diluted EPS
|
-16.38 | 0.00 | 0.23 | 0.11 |
|
Weighted Average Shares
|
1.49 | 507.35 | 16.46 | 24.50 |
|
Diluted Weighted Avg Shares
|
1.49 | 507.35 | 16.46 | 24.50 |
|
Comprehensive Income
|
- | - | - | - |